Global Central Nervous System Disorder Therapy Market To Surpass US $ 202.7 Million By 2028, According To Coherent Market Insights (CMI)



/ EIN News / – SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) – According to Coherent Market Insights, the global market for treatments for central nervous system disorders is estimated at US DOLLARS $ 131.3 million in 2021 and is expected to post a CAGR of 6.4% during the forecast period (2021-2028).

Key trends and analysis of Global Central nervous system Troubles Therapeutic Marlet:

Key market trends include increasing prevalence of central nervous system (CNS) disorders, increasing healthcare spending, increasing product launches and approvals, increasing research and development activities , inorganic activities such as collaborations, etc.

An increasing number of research and development activities aimed at improving the effectiveness of central nervous system treatments is expected to drive the growth of the global central nervous system disorders treatment market. For example, in May 2018, the Epilepsy Foundation of America and the Epilepsy Study Consortium, a group of researchers in the United States, launched a collaborative study known as the Human Epilepsy Project. This study aims to explore the challenges faced by patients with focal seizures who do not respond to medication and to discover new alternatives to overcome these challenges. This study is expected to be completed by September 2022. Research activities such as the Human Epilepsy Project help to study the current response to treatment in patients with CNS disorders and also create opportunities in the global Therapeutic Disorders market. central nervous system.

Request a copy of this report @

Increased health care spending can support research and development activities, which in turn can support research and development of new drugs for the treatment of CNS disorders. This is expected to drive the growth of the global central nervous system disorders treatment market during the forecast period. For example, according to the National Multiple Sclerosis Society, US, in 2021, the US Congress invested US $ 20 million for multiple sclerosis (MS) research as part of the Multiple Sclerosis Research Program.

However, the long duration of the drug approval process and the adverse reactions associated with the treatment of CNS disorders are expected to hamper the growth of the global central nervous system disorder therapeutics market. For example, in November 2018, the United States Food and Drug Administration (FDA) issued a warning regarding the use of the drug Gilenya made by Novartis AG, a Swiss pharmaceutical company, for the treatment of relapsing multiple sclerosis. The United States Food and Drug Administration has stated that Gilenya can cause the disease to worsen when the drug is stopped and can even lead to permanent disability.

Key points of the market:

Increase in product launches and approvals, increase in research and development activities, inorganic activities such as collaborations and others are expected to drive the growth of the global central nervous system disorders treatment market over the course of the year. forecast period. For example, in April 2021, Otsuka Pharmaceutical Co. Ltd., a Japanese pharmaceutical company and H. Lundbeck A / S, a Danish pharmaceutical company announced that they would continue with phase III clinical trials to verify efficacy and safety of the drug brexpiprazole. for the treatment of patients with Alzheimer’s dementia.

The North America region is expected to show rapid growth during the forecast period due to increased product launches and approvals. For example, in April 2021, Biogen, a US biotechnology company received approval from the National Medical Products Administration (NMPA) of China for its new product called TECFIDERA. TECFIDERA is an oral medicine used to treat relapsing multiple sclerosis. This approval will help the company expand its presence in China.

Buy this research report now @

Competitive landscape:

Major players operating in the global central nervous system disorder therapeutics market include Pfizer Inc., Biogen, Otsuka Pharmaceutical Co. Ltd., Merck & Co., AstraZeneca, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Johnson & Johnson Private Limited, Eli Lilly and Company, Sanofi, GlaxoSmithKline plc. and Boehringer Ingelheim International GmbH.

Market segmentation :

  • Global Central Nervous System Disorder Therapy Market, By Disease Type:
    • Neurovascular diseases
    • Central nervous system trauma
    • Mental Health
      • Anxiety disorders
      • Epilepsy
      • Others
    • Degenerative diseases
      • Alzheimer’s disease
      • Parkinson’s disease
      • Multiple sclerosis
      • Others
    • Infectious diseases
    • Central nervous system cancer
    • Others
  • By type of drug:
    • Pain relievers
    • Anesthetics
    • Anti-parkinsonian drugs
    • Anti-epileptics
    • Others
  • By distribution channel:
    • Hospital pharmacies
    • Retail pharmacies
    • Others
  • By region:
    • North America
    • Latin America
      • By country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By country:
        • UK
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • The rest of europe
    • Asia Pacific
      • By country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia-Pacific
    • Middle East
      • By country:
        • CCG
        • Israel
        • Rest of the Middle East
    • Africa
      • By country / region:
        • South Africa
        • central Africa
        • North Africa

Related Market Intelligence Reports:

Immunodeficiency Therapeutics Market, By Therapy Type (Immunoglobulin Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy, and Others), By Test Type (Blood Test & Prenatal Tests), By Disease Type (Deficiency In antibodies, cell immunodeficiency, innate immune disorders and Others), by distribution channel (hospital pharmacy, retail pharmacy and online pharmacy) and by region (North America, Latin America, Europe, Asia-Pacific, Middle East and Africa ) – Size, Share, Outlook and Opportunity Analysis, 2021 – 2028

Learn more:

Polycythemia vera therapeutic market, by disease type (primary polycythemia vera and secondary polycythemia vera), by drug class (antimetabolite, kinase inhibitors, interferon alpha, selective serotonin reuptake inhibitors and others), by route of ‘administration (oral, intravenous, intramuscular, and subcutaneous), by distribution channel (hospital pharmacies, retail pharmacies and online pharmacies) and by region (North America, Latin America, Europe, Asia-Pacific, Middle East and Africa) – Size, Share, Outlook and Opportunity Analysis, 2021 – 2028

Learn more:

About Us:

Consistent market information is a global market intelligence and consulting organization that aims to help our plethora of clients achieve transformational growth by helping them make critical business decisions. Our head office is located in India, we have a sales office in the world financial capital in the United States, and sales consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 57 countries around the world.

Follow us: LinkedIn | Twitter

                  Mr. Shah
                  Senior Client Partner – Business Development
                  Coherent Market Insights
                  US: +1-206-701-6702
                  UK: +44-020-8133-4027
                  Japan: +81-050-5539-1737
                  India: +91-848-285-0837

Main logo


Leave A Reply

Your email address will not be published.